INO-3112 shows robust responses in head and neck cancer
6 November 2015 | By Victoria White
Immunology results show that INO-3112 generated robust HPV16/18 specific CD8+ T cell responses and antibodies against HPV16/18...
List view / Grid view
News
UCART19 used to treat ‘incurable’ leukaemia
6 November 2015 | By Victoria White
A team at Great Ormond Street Hospital has used UCART 19 cells to treat a one-year-old girl who had relapsed acute lymphoblastic leukaemia with positive results...
Novo Nordisk presents findings of obesity care study
5 November 2015 | By Victoria White
Results from the study highlight a general lack of understanding of obesity as a disease and its impact on the body...
Johnson & Johnson to acquire Novira Therapeutics
5 November 2015 | By Victoria White
The acquisition includes Novira's portfolio of novel antivirals, including its lead candidate, NVR 3-778...
Sanofi and Hanmi announce diabetes license agreement
5 November 2015 | By Victoria White
Sanofi and Hanmi have entered a worldwide license agreement to develop a portfolio of experimental, long-acting diabetes treatments...
Dry eye syndrome treatment market value to grow to $4.6b by 2024
5 November 2015 | By Victoria White
GlobalData says this rise will be driven primarily by the introduction of novel drugs, most notably Shire’s lifitegrast, a first-in-class drug with anti-inflammatory benefits...
Saxenda demonstrates significant and sustained weight loss over three years
4 November 2015 | By Victoria White
Saxenda in combination with reduced-calorie diet and increased physical activity also delayed the onset of type 2 diabetes in the three-year extension trial...
Janssen submits application to EMA to expand use of ibrutinib
4 November 2015 | By Victoria White
Janssen-Cilag International has submitted a Type II variation application to the European Medicines Agency (EMA), which seeks to broaden the existing marketing authorisation for Imbruvica (ibrutinib) to include previously untreated patients with chronic lymphocytic leukaemia (CLL).
NEB® launches new NEBNext® Ultra™ II Kit for NGS Library Preparation with as little as 500 pg of input DNA
4 November 2015 | By New England BioLabs, Inc.
New Ultra II technology addresses lower input amounts and challenging sample types for Illumina® next generation sequencing systems...
Phase III study of avelumab in NSCLC starts
4 November 2015 | By Victoria White
Avelumab is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody that potentially uses the body’s own immune system to fight cancer...
Tumour DNA in blood can be used to track cancers
4 November 2015 | By Victoria White
Scientists have shown that tumour DNA shed into the bloodstream can be used to track cancers in real time as they evolve and respond to treatment...
Allergan and Mimetogen to develop tavilermide for dry eye disease
4 November 2015 | By Victoria White
Tavilermide is differentiated from other investigational therapies in dry eye disease because it induces the production of mucin...
ESCMID calls for universal flu vaccination for healthcare works
4 November 2015 | By Victoria White
ESCMID believes that one vital tool to increase the adoption of flu vaccinations among healthcare professionals is to establish hospital-based league tables throughout Europe...
NICE recommends Ikervis in final draft guidance
4 November 2015 | By Victoria White
Ikervis has been recommended for the treatment of keratitis in adults with dry eye disease who have not responded to tear substitutes...
MHRA helps make dementia medicine packaging more user-friendly
4 November 2015 | By Victoria White
From June 2016, medicines for the treatment of dementia will include the days of the week clearly on the blister packs...
